IQ-AI stock analysis
Want to see GB:IBAI full AI Analyst Report?
IQ-AI (IBAI) Share Price & Analysis
IBAI Stock Chart & Stats
- Day’s Range
- GBX 0.70 - GBX 0.75
- 52-Week Range
- GBX 0.40 - GBX 1.45
- Previous Close
- GBX 0.73
- Volume
- N/A
- Average Volume (3M)
- 235.37K
- Market Cap
- GBP 1.79M
- Enterprise Value
- GBP 2.04M
- Total Cash (Recent Filing)
- GBP 49.38K
- Total Debt (Recent Filing)
- GBP 177.45K
- Price to Earnings (P/E)
- ―
- Beta
- 1.03
- Next Earnings
- Apr 29, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Apr 06, 2011
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Steady revenue expansion indicates that IQ-AI has continued to increase commercial activity over several years rather than relying solely on a temporary uplift. A larger revenue base can improve operating leverage and provide a foundation for future earnings improvement if cost control strengthens.
Strong Gross Margin
An approximately 82% gross margin points to favorable underlying economics in the company’s products or services. Maintaining this level gives IQ-AI meaningful scope to cover operating costs, reinvest in growth, and convert additional revenue into improved profitability as scale develops.
Positive Free Cash Flow
The shift to positive operating and free cash flow is an important improvement after negative cash flow during 2020–2024. If sustained, internally generated cash could reduce reliance on external financing, support ongoing operations, and provide greater flexibility while the company works toward profitability.
Bears Say
Persistent Net Losses
The company has not yet demonstrated sustainable earnings despite revenue growth and strong gross margins. A net loss equal to roughly 51% of revenue indicates that operating expenses remain too high relative to gross profit, limiting reinvestment capacity and increasing dependence on future financial improvement.
Reduced Balance-Sheet Flexibility
The sharp reduction in equity has weakened the company’s financial cushion, while the move from zero reported debt in 2023–2024 to leverage of about 0.73x equity increases financing pressure. Continued losses could further constrain funding options and reduce resilience if profitability does not improve.
Volatile Cash Generation
Although 2025 free cash flow was positive, the preceding multi-year cash burn shows that cash generation is not yet established as a dependable capability. Volatility makes planning and investment more difficult, and a renewed cash shortfall could increase financing needs while losses persist.
IQ-AI News
IBAI FAQ
What was IQ-AI ’s price range in the past 12 months?
What is IQ-AI ’s market cap?
When is IQ-AI ’s upcoming earnings report date?
How were IQ-AI ’s earnings last quarter?
Is IQ-AI overvalued?
Does IQ-AI pay dividends?
What is IQ-AI ’s EPS estimate?
How many shares outstanding does IQ-AI have?
What happened to IQ-AI ’s price movement after its last earnings report?
Which hedge fund is a major shareholder of IQ-AI ?
What is the TipRanks Smart Score and how is it calculated?
Company Description
IQ-AI
Imaging Biometrics Ltd., founded in 1965 and headquartered in Saint Helier, Jersey, specializes in medical imaging diagnostics and clinical patient care. The company extends its services across the United Kingdom, Switzerland, the European Union, and the United States. Its operations are structured into three main segments: a Holding Company, Medical Software, and Oral Gallium Maltolate (GaM). The Medical Software division develops a comprehensive suite of ready-to-use software applications for the healthcare sector. This portfolio includes IB Clinic, which serves as the foundational platform for all IB software; IB Neuro, a specialized platform for MR DSC perfusion processing; and IB Delta Suite, designed to generate Delta T1 maps from routine MR examinations. Further offerings comprise IB DCE and IB Diffusion, both providing in-depth insights into blood flow and water diffusion throughout the body. For non-invasive assessments, the company provides StoneChecker and Liver Surface Nodularity, which are computed tomography (CT) processing tools that assist clinicians in evaluating kidney stones and liver health. Additional software includes IB ASL, used to measure cerebral blood flow for diagnosing conditions like stroke and dementia, and IB Zero G, an innovative technology that eliminates the need for gadolinium contrast agents in standard imaging. The suite also features IB Nimble, facilitating virtual collaboration among healthcare professionals. Beyond software, the company's Oral Gallium Maltolate (GaM) segment is actively pursuing the development of IB003, a gallium maltolate drug candidate currently in Phase 1 clinical trials for treating glioblastoma. Imaging Biometrics Ltd. also offers consulting services. The entity, which was previously known as IQ-AI Limited, is slated to adopt the name Imaging Biometrics Ltd. in May 2025.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Trevor Edward Brown
- Employees
- 7
- Website
- www.imagingbiometrics.com
- Address
- IFC5, Saint Helier, JE, JE1 1ST, JE
IQ-AI (IBAI) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 1 | 0 | 11 |









